Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $705.17 million. The enterprise value is $489.22 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 86.95 million shares outstanding. The number of shares has increased by 195.51% in one year.
| Current Share Class | 86.95M |
| Shares Outstanding | 86.95M |
| Shares Change (YoY) | +195.51% |
| Shares Change (QoQ) | +4.37% |
| Owned by Insiders (%) | 3.35% |
| Owned by Institutions (%) | 56.22% |
| Float | 69.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 51.89 |
| Forward PS | n/a |
| PB Ratio | 2.85 |
| P/TBV Ratio | 3.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 54.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.08 |
| Quick Ratio | 4.00 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -194.63% and return on invested capital (ROIC) is -62.37%.
| Return on Equity (ROE) | -194.63% |
| Return on Assets (ROA) | -49.34% |
| Return on Invested Capital (ROIC) | -62.37% |
| Return on Capital Employed (ROCE) | -82.53% |
| Revenue Per Employee | $76,619 |
| Profits Per Employee | -$2.48M |
| Employee Count | 118 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.93% in the last 52 weeks. The beta is 2.06, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.06 |
| 52-Week Price Change | -47.93% |
| 50-Day Moving Average | 8.35 |
| 200-Day Moving Average | 11.62 |
| Relative Strength Index (RSI) | 56.70 |
| Average Volume (20 Days) | 1,500,809 |
Short Selling Information
The latest short interest is 11.13 million, so 12.80% of the outstanding shares have been sold short.
| Short Interest | 11.13M |
| Short Previous Month | 9.52M |
| Short % of Shares Out | 12.80% |
| Short % of Float | 16.01% |
| Short Ratio (days to cover) | 8.82 |
Income Statement
In the last 12 months, Immunome had revenue of $9.04 million and -$292.96 million in losses. Loss per share was -$5.00.
| Revenue | 9.04M |
| Gross Profit | -120.50M |
| Operating Income | -153.46M |
| Pretax Income | -232.03M |
| Net Income | -292.96M |
| EBITDA | -151.89M |
| EBIT | -153.46M |
| Loss Per Share | -$5.00 |
Full Income StatementBalance Sheet
The company has $217.30 million in cash and $4.83 million in debt, giving a net cash position of $212.47 million or $2.44 per share.
| Cash & Cash Equivalents | 217.30M |
| Total Debt | 4.83M |
| Net Cash | 212.47M |
| Net Cash Per Share | $2.44 |
| Equity (Book Value) | 181.17M |
| Book Value Per Share | 2.81 |
| Working Capital | 167.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$110.79 million and capital expenditures -$53.51 million, giving a free cash flow of -$164.30 million.
| Operating Cash Flow | -110.79M |
| Capital Expenditures | -53.51M |
| Free Cash Flow | -164.30M |
| FCF Per Share | -$1.89 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,697.33% |
| Pretax Margin | -3,240.38% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -195.51% |
| Shareholder Yield | -195.51% |
| Earnings Yield | -41.75% |
| FCF Yield | -23.42% |
Analyst Forecast
The average price target for Immunome is $26.00, which is 220.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.00 |
| Price Target Difference | 220.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 103.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 4.82 and a Piotroski F-Score of 1.
| Altman Z-Score | 4.82 |
| Piotroski F-Score | 1 |